PBYI Q1 2025 Earnings — Puma Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

PBYIPuma Biotechnology, Inc.

$311M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$46M+5.1% YoY

Gross Profit

$35M77.1% margin

Operating Income

$4M8.7% margin

Net Income

$3M6.5% margin

EPS (Diluted)

$0.06

QoQ Revenue Growth

-22.1%

Cash Flow

Operating Cash Flow

$4M

Free Cash Flow

$4M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$196M

Total Liabilities

$99M

Stockholders' Equity

$97M

Cash & Equivalents

$63M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$46M	$44M	+5.1%
Gross Profit	$35M	$33M	+7.3%
Operating Income	$4M	-$2M	+273.3%
Net Income	$3M	-$5M	+161.8%

Revenue Segments

Product

$43M94%

Royalty

$3M6%